Stephanie A Robertson

US Patent:

6924117, Aug 2, 2005

Filed:

Jul 18, 2001

Appl. No.:

09/908419

Inventors:

Mario N. Lioubin - San Mateo CA, US
Lori Friedman - San Francisco CA, US
Marcia Belvin - Berkeley CA, US
Jeffery S. Larson - Burlingame CA, US
Changyou Chen - Castro Valley CA, US
Stephanie A. Robertson - San Francisco CA, US
Wen Shi - San Francisco CA, US
Jocelyn Chan - San Francisco CA, US
Danxi Li - San Francisco CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C12Q001/68
A61K039/395
A01N037/18

US Classification:

435 723, 4241301, 4241781, 424 941, 514 2

Abstract:

Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.

US Patent:

6927022, Aug 9, 2005

Filed:

Jul 10, 2002

Appl. No.:

10/192353

Inventors:

Lori Friedman - San Francisco CA, US
Gregory D. Plowman - San Carlos CA, US
Roel P. Funke - South San Francisco CA, US
Marcia Belvin - Albany CA, US
Danxi Li - San Francisco CA, US
Stephanie A. Robertson - San Francisco CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

G01N033/50

US Classification:

435 4, 436501

Abstract:

Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.

US Patent:

20030165497, Sep 4, 2003

Filed:

Jan 23, 2002

Appl. No.:

10/056790

Inventors:

Mario Lioubin - San Mateo CA, US
Lori Friedman - San Francisco CA, US
Marcia Belvin - Albany CA, US
Jeffrey Larson - Burlingame CA, US
Changyou Chen - Castro Valley CA, US
Stephanie Robertson - San Francisco CA, US
Wen Shi - San Francisco CA, US
Jocelyn Chan - San Francisco CA, US
Danxi Li - San Francisco CA, US
Helen Francis-Lang - San Francisco CA, US
Gregory Plowman - San Carlos CA, US
Roel Funke - South San Francisco CA, US
Michael Schoor - Leverkusen, DE
Branko Zevnik - Leverkusen, DE
Gunther Kauselmann - Koeln, DE
Hartmut Tintrup - Cologne, DE

International Classification:

G01N033/574
A61K039/395

US Classification:

424/141100, 424/146100, 424/155100, 435/007230

Abstract:

RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.

US Patent:

20040161827, Aug 19, 2004

Filed:

Feb 5, 2004

Appl. No.:

10/773714

Inventors:

Andrew Buchman - Berkeley CA, US
Darren Platt - San Francisco CA, US
Michael Ollmann - Menlo Park CA, US
Lynn Young - Redwood City CA, US
Madelyn Demsky - San Francisco CA, US
Kevin Keegan - San Lorenzo CA, US
Lori Friedman - San Francisco CA, US
Casey Kopczynski - Belmont CA, US
Jeffrey Larson - Burlingame CA, US
Stephanie Robertson - San Francisco CA, US

International Classification:

A01K067/033
C07H021/04
C12N009/99
C12N005/06

US Classification:

435/069200, 435/184000, 435/320100, 435/348000, 536/023200, 800/008000

Abstract:

A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.

US Patent:

20050181481, Aug 18, 2005

Filed:

Apr 11, 2005

Appl. No.:

11/103035

Inventors:

Lori Friedman - San Francisco CA, US
Gregory Plowman - San Carlos CA, US
Roel Funke - South San Francisco CA, US
Marcia Belvin - Albany CA, US
Danxi Li - San Francisco CA, US
Stephanie Robertson - San Francisco CA, US

International Classification:

C12P021/02
C07H021/04
C07K014/705

US Classification:

435069100, 536023500, 530350000, 435320100, 435325000

Abstract:

Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.

US Patent:

20050186200, Aug 25, 2005

Filed:

Apr 11, 2005

Appl. No.:

11/103068

Inventors:

Lori Friedman - San Francisco CA, US
Gregory Plowman - San Carlos CA, US
Roel Funke - South San Francisco CA, US
Marcia Belvin - Albany CA, US
Danxi Li - San Francisco CA, US
Stephanie Robertson - San Francisco CA, US

International Classification:

A61K039/395
A61K038/22

US Classification:

424130100, 514012000

Abstract:

Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.

US Patent:

20100275275, Oct 28, 2010

Filed:

Aug 5, 2009

Appl. No.:

12/536466

Inventors:

Lori Friedman - San Francisco CA, US
Gregory D. Plowman - San Carlos CA, US
Roel P. Funke - South San Francisco CA, US
Marcia Belvin - Albany CA, US
Danxi Li - San Francisco CA, US
Stephanie A. Robertson - San Francisco CA, US

Assignee:

EXELIXIS INC. - South San Francisco CA

International Classification:

G01N 33/53
C12Q 1/68
C12Q 1/32

US Classification:

800 3, 435 6, 435 721, 435 26

Abstract:

Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.

US Patent:

6762291, Jul 13, 2004

Filed:

Mar 13, 2000

Appl. No.:

09/524101

Inventors:

Andrew Roy Buchman - Berkeley CA
Darren Mark Platt - San Francisco CA
Michael Martin Ollman - Menlo Park CA
Lynn Marie Young - Redwood City CA
Madelyn Robin Demsky - San Francisco CA
Kevin Patrick Keegan - San Lorenzo CA
Lori Friedman - San Francisco CA
Casey Kopczynski - Belmont CA
Jeffrey S. Larson - Burlingame CA
Stephanie A. Robertson - San Francisco CA

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C12Q 168

US Classification:

536 231, 435 5, 435 6, 435 911, 435 912, 530350, 530351

Abstract:

A family of p53 tumor suppressor nucleic acid and protein isolated from several insect species is described. The p53 nucleic acid and protein can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in p53 expression or mis-expression. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds that are potential pesticidal agents or therapeutics that interact with p53 protein. They can also be used in methods for studying p53 activity and identifying other genes that modulate the function of, or interact with, the p53 gene. Nucleic acid and protein sequences for Drosophila p33 and Rb tumor suppressors are also described.